
Geoffrey Owen Littlejohn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6174114/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet, The, 2021, 397, 2098-2110.	6.3	440
2	Fibromyalgia. Nature Reviews Disease Primers, 2015, 1, 15022.	18.1	308
3	Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain, 1994, 58, 185-193.	2.0	272
4	Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis and Rheumatism, 1993, 36, 642-646.	6.7	244
5	Fibromyalgia syndrome. Journal of Rheumatology, 2007, 34, 1415-25.	1.0	129
6	Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. Nature Reviews Rheumatology, 2015, 11, 639-648.	3.5	118
7	Neurogenic inflammation in fibromyalgia. Seminars in Immunopathology, 2018, 40, 291-300.	2.8	86
8	Models of adjustment to chronic illness: Using the example of rheumatoid arthritis. Clinical Psychology Review, 2004, 24, 461-488.	6.0	78
9	Metabolic Factors in Diffuse Idiopathic Skeletal Hyperostosis – A Review of Clinical Data. Open Rheumatology Journal, 2014, 8, 116-128.	0.1	68
10	Clinical evaluation of intraâ€articular injections for lumbar facet joint pain. Medical Journal of Australia, 1985, 143, 563-565.	0.8	64
11	Insulin and new bone formation in diffuse idiopathic skeletal hyperostosis. Clinical Rheumatology, 1985, 4, 294-300.	1.0	63
12	A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia. Clinical Journal of Pain, 2009, 25, 365-375.	0.8	63
13	Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis Annals of the Rheumatic Diseases, 1992, 51, 1318-1321.	0.5	59
14	The use of opioids in fibromyalgia. International Journal of Rheumatic Diseases, 2011, 14, 6-11.	0.9	57
15	Barriers to Optimal Disease Control for Rheumatoid Arthritis Patients With Moderate and High Disease Activity. Arthritis Care and Research, 2014, 66, 190-196.	1.5	56
16	Fibromyalgia Syndrome and Disease Activity in Systemic Lupus Erythematosus. Lupus, 1994, 3, 187-191.	0.8	53
17	Fibromyalgia and Disability: Report of the Moss International Working Group on Medico-Legal Aspects of Chronic Widespread Musculoskeletal Pain Complaints and Fibromyalgia. Scandinavian Journal of Rheumatology, 1995, 24, 112-118.	0.6	52
18	Measuring quality of life in rheumatic conditions. Clinical Rheumatology, 2007, 26, 671-673.	1.0	50

#	Article	IF	CITATIONS
19	Fibrositis/Fibromyalgia Syndrome in the Workplace. Rheumatic Disease Clinics of North America, 1989, 15, 45-60.	0.8	48
20	The SMILE Study — Safety of Methotrexate in Combination with Leflunomide in Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 228-235.	1.0	41
21	Radiographic features of the hand in diffuse idiopathic skeletal hyperostosis (DISH): comparison with normal subjects and acromegalic patients Radiology, 1981, 140, 623-629.	3.6	39
22	Prevalence of Myofascial Pain Syndrome in Fibromyalgia Syndrome and Regional Pain Syndrome:. Journal of Musculoskeletal Pain, 1993, 1, 19-35.	0.3	38
23	Towards epidemiological criteria for soft-tissue disorders of the arm. Occupational Medicine, 2003, 53, 313-319.	0.8	38
24	The use of unproven remedies for rheumatoid arthritis in Australia. Medical Journal of Australia, 1985, 143, 516-518.	0.8	38
25	LUPUS AND NON-LUPUS CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Australian and New Zealand Journal of Medicine, 1987, 17, 501-506.	0.5	37
26	Evidence for the improvement of fatigue in fibromyalgia: A 4â€week left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation randomizedâ€controlled trial. European Journal of Pain, 2018, 22, 1255-1267.	1.4	37
27	Fibromyalgia remains a significant burden in rheumatoid arthritis patients in Australia. International Journal of Rheumatic Diseases, 2018, 21, 639-646.	0.9	37
28	Diffuse idiopathic skeletal hyperostosis and new bone formation in male gouty subjects. Rheumatology International, 1982, 2, 83-86.	1.5	36
29	Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. Rheumatology, 1999, 38, 59-65.	0.9	35
30	Pregnancy outcome in systemic lupus erythematosus (SLE): a review of 54 cases. Australian and New Zealand Journal of Medicine, 1998, 28, 18-22.	0.5	34
31	Modulation of NMDA Receptor Activity in Fibromyalgia. Biomedicines, 2017, 5, 15.	1.4	32
32	Neuroticism in Young Women with Fibromyalgia Links to Key Clinical Features. Pain Research and Treatment, 2012, 2012, 1-7.	1.7	30
33	The diagnosis and classification of scleroderma (systemic sclerosis). Postgraduate Medical Journal, 1988, 64, 121-125.	0.9	29
34	Fibromyalgia Syndrome: Which Antidepressant Drug Should We Choose. Current Pharmaceutical Design, 2006, 12, 3-9.	0.9	29
35	Psychological factors mediate key symptoms of fibromyalgia through their influence on stress. Clinical Rheumatology, 2016, 35, 2353-2357.	1.0	29
36	Methotrexate use in systemic lupus erythematosus. Lupus, 1997, 6, 385-389.	0.8	27

Geoffrey Owen Littlejohn

#	Article	IF	CITATIONS
37	A unique presentation of multicentric reticulohistiocytosis in pregnancy. Arthritis and Rheumatism, 1993, 36, 269-272.	6.7	25
38	International travel in the immunocompromised patient: a cross-sectional survey of travel advice in 254 consecutive patients. Internal Medicine Journal, 2015, 45, 618-623.	0.5	23
39	WEGENER'S GRANULOMATOSIS: CLINICAL FEATURES AND OUTCOME IN SEVENTEEN PATIENTS. Australian and New Zealand Journal of Medicine, 1985, 15, 241-245.	0.5	22
40	NEUROPSYCHIATRIC MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. Australian and New Zealand Journal of Medicine, 1988, 18, 679-684.	0.5	22
41	The Effects of Dietary Fibre on Glucose Tolerance in Healthy Males. Australian and New Zealand Journal of Medicine, 1979, 9, 154-158.	0.5	21
42	Key Milestones Contributing to the Understanding of the Mechanisms Underlying Fibromyalgia. Biomedicines, 2020, 8, 223.	1.4	21
43	Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clinical Rheumatology, 2020, 39, 2545-2551.	1.0	21
44	Diseaseâ€modifying antiâ€rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in communityâ€based practice. Internal Medicine Journal, 2011, 41, 450-455.	0.5	20
45	Fibromyalgia onset has a high impact on work ability in Australians. Internal Medicine Journal, 2016, 46, 1069-1074.	0.5	20
46	A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. International Journal of Rheumatic Diseases, 2013, 16, 532-538.	0.9	19
47	Psychological control is a key modulator of fibromyalgia symptoms and comorbidities. Journal of Pain Research, 2012, 5, 463.	0.8	18
48	Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment. Internal Medicine Journal, 2004, 34, 626-638.	0.5	17
49	Terminology, criteria, and definitions in complex regional pain syndrome: challenges and solutions. Journal of Pain Research, 2015, 8, 871.	0.8	17
50	Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the <scp>PREDICT</scp> study. International Journal of Rheumatic Diseases, 2017, 20, 460-468.	0.9	17
51	The Fibromyalgia Bladder Index. Clinical Rheumatology, 2007, 26, 2097-2103.	1.0	16
52	Is there a role for opioids in the treatment of fibromyalgia?. Pain Management, 2016, 6, 347-355.	0.7	16
53	Regional pain syndrome: clinical characteristics, mechanisms and management. Nature Clinical Practice Rheumatology, 2007, 3, 504-511.	3.2	15
54	Central sensitivity and fibromyalgia. Internal Medicine Journal, 2021, 51, 1990-1998.	0.5	14

4

GEOFFREY OWEN LITTLEJOHN

#	Article	IF	CITATIONS
55	Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger?. Postgraduate Medical Journal, 1991, 67, 632-637.	0.9	13
56	Rumination modulates stress and other psychological processes in fibromyalgia. European Journal of Rheumatology, 2015, 2, 143-148.	1.3	13
57	Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational Study. Journal of Rheumatology, 2015, 42, 1603-1609.	1.0	12
58	Bisphosphonates for early complex regional pain syndrome. Nature Reviews Rheumatology, 2013, 9, 199-200.	3.5	11
59	Honing fibromyalgia diagnosis. Nature Reviews Rheumatology, 2014, 10, 267-269.	3.5	11
60	The role of sex hormones in pain response. Pain, 1999, 83, 112-113.	2.0	8
61	Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia. Clinical Rheumatology, 2022, 41, 53-62.	1.0	7
62	Chronic pain syndromes: overlapping phenotypes with common mechanisms. F1000Research, 2019, 8, 255.	0.8	7
63	Fibromyalgia: current diagnosis and management. Expert Review of Clinical Immunology, 2009, 5, 181-192.	1.3	6
64	Whiplash: Same Elephant, Different Room. Journal of Rheumatology, 2014, 41, 411-413.	1.0	6
65	The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice. International Journal of Rheumatology, 2017, 2017, 1-8.	0.9	6
66	The Radiographic Changes of Scleroderma in the Hands. Journal of Medical Imaging and Radiation Oncology, 1990, 34, 53-58.	0.6	5
67	Primary care and specialist management options. Best Practice and Research in Clinical Rheumatology, 1999, 13, 469-477.	1.4	5
68	Neuroinflammation in fibromyalgia and CRPS: top-down or bottom-up?. Nature Reviews Rheumatology, 2016, 12, 242-242.	3.5	5
69	Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL dataset. Clinical Rheumatology, 2022, 41, 1105-1114.	1.0	5
70	Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis. European Journal of Rheumatology, 2021, 8, 67-72.	1.3	4
71	Australian and New Zealand evidenceâ€based recommendations for pain management by pharmacotherapy in adult patients with inflammatory arthritis. International Journal of Rheumatic Diseases, 2014, 17, 738-748.	0.9	3
72	Pharmacological Treatment of Fibromyalgia. , 2021, , 33-52.		3

GEOFFREY OWEN LITTLEJOHN

#	Article	IF	CITATIONS
73	Complex regional pain syndrome. Rheumatology, 2014, 53, 1157-1158.	0.9	2
74	Management strategies for fibromyalgia. Open Access Rheumatology: Research and Reviews, 2011, 3, 47.	0.8	1
75	Targeting fibromyalgia pain: brain–spinal cord and peripheral contributions. International Journal of Clinical Rheumatology, 2011, 6, 463-474.	0.3	1
76	Muscle Changes in RSI: Is the Elephant in the Room?. Journal of Musculoskeletal Pain, 2012, 20, 269-270.	0.3	1
77	Drs. Littlejohn and Guymer reply. Journal of Rheumatology, 2014, 41, 2324-2324.	1.0	1
78	Fibromyalgia and psoriatic arthritis: Partners together. International Journal of Rheumatic Diseases, 2021, 24, 141-143.	0.9	1
79	Reply to Dr. Starlanyl. Journal of Musculoskeletal Pain, 1994, 2, 147-149.	0.3	Ο
80	Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL. Internal Medicine Journal, 2018, 48, 1185-1192.	0.5	0
81	Dynamic CTA and MRA in a case of severe Raynaud's phenomenon. Clinical Imaging, 2020, 66, 133-136.	0.8	Ο
82	What is a patient?. Medical Journal of Australia, 1986, 145, 60-60.	0.8	0